These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33093086)

  • 21. Safety profile of the antiviral drug remdesivir: An update.
    Fan Q; Zhang B; Ma J; Zhang S
    Biomed Pharmacother; 2020 Oct; 130():110532. PubMed ID: 32707440
    [No Abstract]   [Full Text] [Related]  

  • 22. The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access.
    Goldstein RH; Walensky RP
    JAMA; 2020 Dec; 324(21):2151-2152. PubMed ID: 33175110
    [No Abstract]   [Full Text] [Related]  

  • 23. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R
    Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covid-19: Remdesivir has "small effect" against death or progression to ventilation, WHO trial finds.
    Mahase E
    BMJ; 2022 May; 377():o1118. PubMed ID: 35508315
    [No Abstract]   [Full Text] [Related]  

  • 25. Leaks of Clinical Trial Data and Research Integrity.
    Rajkumar SV; Sampathkumar P
    Mayo Clin Proc; 2020 Jul; 95(7):1318-1319. PubMed ID: 32622439
    [No Abstract]   [Full Text] [Related]  

  • 26. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL;
    Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308
    [No Abstract]   [Full Text] [Related]  

  • 27. Remdesivir for the Treatment of COVID-19.
    Allen R; Turner M; deSouza IS
    Am Fam Physician; 2022 Feb; 105(2):131-132. PubMed ID: 35166509
    [No Abstract]   [Full Text] [Related]  

  • 28. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.
    Enoki Y; Igarashi Y; Watabe Y; Honma K; Suzuki Y; Hayashi Y; Hiraoka K; Taguchi K; Matsumoto K
    J Glob Antimicrob Resist; 2021 Mar; 24():81-82. PubMed ID: 33307274
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of SARS-CoV-2: How far have we reached?
    Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
    Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 31. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.
    Tempestilli M; Stazi GV; Maffongelli G; Marini MC; Ascoli Bartoli T; Ippolito G; Nicastri E; Marchioni L; Agrati C
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1583-1585. PubMed ID: 33982133
    [No Abstract]   [Full Text] [Related]  

  • 32. Major Update 2: Remdesivir for Adults With COVID-19.
    Finsterer J
    Ann Intern Med; 2022 Aug; 175(8):W81. PubMed ID: 35969872
    [No Abstract]   [Full Text] [Related]  

  • 33. Major Update 2: Remdesivir for Adults With COVID-19.
    Kaka AS; Wilt TJ
    Ann Intern Med; 2022 Aug; 175(8):W81-W82. PubMed ID: 35969873
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical course and serial chest ultra-low-dose CT findings in a patient with COVID-19 treated with remdesivir.
    Grazioli-Gauthier L; Vanini G; Argentieri G; Bernasconi E; Gianella P
    Minerva Med; 2021 Aug; 112(4):516-518. PubMed ID: 34269015
    [No Abstract]   [Full Text] [Related]  

  • 35. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 36. [The medicinal treatment of COVID-19: a brief update].
    de Boer MGJ; Gieling EM; van der Linden PD; Sinha BNM; Vollaard AM
    Ned Tijdschr Geneeskd; 2020 Nov; 164():. PubMed ID: 33331727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data.
    Giacomelli A; Cozzi-Lepri A; Casalini G; Oreni L; Ridolfo AL; Antinori S
    Pharmacol Res; 2022 Jul; 181():106268. PubMed ID: 35605811
    [No Abstract]   [Full Text] [Related]  

  • 38. Regulatory approval for COVID-19 across the globe.
    Mahalmani V; Pugazhenthan T; Mittal N; Varthya SB; Medhi B
    Indian J Pharmacol; 2020; 52(6):457-466. PubMed ID: 33666185
    [No Abstract]   [Full Text] [Related]  

  • 39. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
    Chua KP; Conti RM
    JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187
    [No Abstract]   [Full Text] [Related]  

  • 40. Repurposing antimalarials and other drugs for COVID-19.
    Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
    Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.